iRhythm Shares Hit 52-Week Low After a $29.9 Million GAAP Q3 Loss

iRhythm Holdings, Inc. shares reached a new 52-week low Friday, Nov. 6, as the company reported a $29.9 million GAAP loss and higher third-quarter revenue.

The company recorded $221.6 million in third-quarter revenue, up 14.9% year over year. Adjusted net income was $27.8 million, or $0.82 per diluted share, and adjusted EBITDA totaled $51.2 million. The figures show revenue growth and adjusted income alongside a GAAP net loss.

iRhythm expects to submit its Zio MCT filing to the Food and Drug Administration (FDA) in 2027. Zio MCT is the company’s upcoming mobile cardiac product. The filing timeline and a 2026 revenue outlook of $890 million to $895 million were previously disclosed in earlier coverage of iRhythm’s outlook and Zio MCT filing. The company also reiterated a target for an adjusted EBITDA margin of at least 15% in 2027.